PD22-06 EFFICACY OF PENILE TRACTION THERAPY AMONG PATIENTS UNDERGOING INTRALESIONAL INTERFERON TREATMENT FOR PEYRONIE’S DISEASE

Abstract

You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Peyronie's Disease1 Apr 2014PD22-06 EFFICACY OF PENILE TRACTION THERAPY AMONG PATIENTS UNDERGOING INTRALESIONAL INTERFERON TREATMENT FOR PEYRONIE’S DISEASE Landon Trost, Taylor Peak, Ronny Tan, Suresh Sikka, and Wayne JG. Hellstrom Landon TrostLandon Trost More articles by this author , Taylor PeakTaylor Peak More articles by this author , Ronny TanRonny Tan More articles by this author , Suresh SikkaSuresh Sikka More articles by this author , and Wayne JG. HellstromWayne JG. Hellstrom More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1857AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Peyronie’s disease (PD) is a fibrosing condition, characterized by penile curvature and is managed with oral, topical, intralesional, and surgical therapies. Currently, controversy exists regarding the role and efficacy of penile traction therapy (PTT) concomitant with intralesional injection (ILI) therapy for PD. We sought to evaluate the efficacy of PTT on PD variables among patients undergoing ILI with interferon alpha-2b (IFN). METHODS A retrospective chart review of all patients undergoing IFN therapy during 2001-2012 was performed. Charts were reviewed for demographic information, objective measures of penile curvature, and vascular status (via penile duplex Doppler ultrasonography). Statistical analyses were performed to compare outcomes of patients using routine PTT versus patients not using PTT. All patients underwent IFN therapy for PD. RESULTS One-hundred, twenty-four patients underwent a median of 12 IFN injections (range 6-24). Mean age was 54 years (range 25-76), and mean pre-treatment curvature was 42.4° (SD 18.6°). Forty-two patients (34%) reported regular use of PTT during the study period. PTT did not impact change in curvature (PTT 7.6° [SD 16.2°] vs. no PTT 9.6° [SD 12.0°], p=0.48) or penile length (PTT +0.04cm [SD 1.2] vs. no PTT +0.13cm [SD 0.8], p=0.67) and was associated with minimal worsening of end-diastolic velocity (PTT 2.0cm/sec [SD 5.9] vs no PTT -1.7cm/sec [SD 4.9], p=0.01). PTT use did not correlate with patient age (p=0.88), pre-treatment erectile function (p=0.53), BMI (p=0.31), years with PD (p=0.65), pre-treatment curvature (p=0.96), changes in peak systolic velocity (p=0.18), or resistive index (0.38). CONCLUSIONS From this data, routine use of PTT during IFN therapy for PD does not affect outcome of therapy related to improvements in penile curvature, length, or vascular status. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e674 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Landon Trost More articles by this author Taylor Peak More articles by this author Ronny Tan More articles by this author Suresh Sikka More articles by this author Wayne JG. Hellstrom More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...